Loading
People with cirrhosis or chronic hepatitis B get a liver ultrasound and a blood test every six months so cancer is caught while it is still curable.
Six-monthly ultrasound with or without AFP is recommended by AASLD, EASL and APASL; it detects HCC at an early stage in ~60-70% of adherent patients and is associated with better survival in cohort studies (no randomised trial outside China). Uptake is under 25% in many health systems. Abbreviated MRI, GALAD (gender, age, AFP-L3, AFP, DCP) and cfDNA methylation tests are being evaluated to improve sensitivity in obese and fatty-liver patients.
Risk-stratified imaging of a defined at-risk population (cirrhosis of any cause, HBV carriers) at an interval matched to tumour doubling time.
Query for this technology: (TITLE:"HCC surveillance in cirrhosis" OR ABSTRACT:"HCC surveillance in cirrhosis" OR TITLE:"ultrasound + AFP" OR ABSTRACT:"ultrasound + AFP") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HCC surveillance in cirrhosis (ultrasound + AFP), not a curated reading list.
Shares Ultrasound, MRI, The hardest cancers are found late, Hepatocellular carcinoma.
Shares Serum tumour markers: proper use and misuse, Ultrasound, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares Alpha-fetoprotein (AFP), Hepatoblastoma.
Shares Hepatitis B and C as cancer causes, Hepatocellular carcinoma.
Shares Early hepatocellular carcinoma (BCLC 0 and A), Hepatocellular carcinoma.
Shares Hepatitis B and C as cancer causes, Hepatocellular carcinoma.
Shares Multi-cancer early detection (MCED), The hardest cancers are found late, Hepatocellular carcinoma.
Shares Hepatoblastoma, Hepatocellular carcinoma.